AAPP Scientific Poster Session Abstracts

"Escaping Addiction: Creating a Path to Recovery": a novel escape room game Alcohol Use Disorder Education/Training/Stigma Opioid Use Disorder Substance Use Disorders Suicide Interdisciplinary Education

'Tranq’: Perceptions of Xylazine and Harm Reduction Practices Among People Receiving Treatment for Substance Use Disorders Harm Reduction Opioid Use Disorder Substance Use Disorders Xylazine

A Comparative Analysis of Metabolic Monitoring for Second Generation Antipsychotics (SGAs) in an Outpatient Psychiatry Clinic for Patients with and without Pharmacist Co-Management Antipsychotics Bipolar Disorder Long-Acting Injectable Major Depression Monitoring Schizophrenia Sleep Disorder Metabolic Monitoring Collaborative Practice Agreement BCPP

A Managed Healthcare Integrated Care Program for Severe Mental Illness (SMI) Bipolar Disorder Health Equity Schizophrenia Care Program Health Insurance

A Novel Advanced Pharmacy Practice Experience (APPE): Scientific Writing with a Focus in Psychiatric Pharmacotherapy Scientific Writing Avanced Pharmacy Practice Experience

A Pharmacist-Driven Therapeutic Drug Monitoring Program for Mood Stabilizers Adherence Bipolar Disorder Major Depression Monitoring Neurology Therapeutic Drug Monitoring Mood Stabilizers

A Retrospective Review of Changes in Rate of Psychosis - Related Inpatient Psychiatric Admissions and Recent Stimulant Prescriptions at a Non-Profit Psychiatric Facility COVID-19 Stimulants Psychosis

A Student-led, Free Clinic Provides Access to Naloxone In An Underserved Population Education/Training/Stigma Health Equity Opioid Use Disorder Substance Use Disorders

Acute Suicidal Ideation and Thoughts of Self-harm with Valbenazine Monitoring Schizophrenia Suicide Tardive Dyskinesia VMAT2 Inhibitor Self-Harm Suicidality

Alcohol Use Relapse Rates for Patients with Liver Transplants in Early vs Standard Transplant Timeline Adherence Alcohol Use Disorder Substance Use Disorders VA

Alice in Wonderland Syndrome Associated with Topiramate Monitoring Neurology Pain

An Outpatient Pharmacist Consultation Service to Help Address a Psychiatry Waitlist Crisis: Protocol for Implementation and Program Evaluation Outpatient Pharmacy Practice Medication Assessment Consultative Services Mental Health Pharmacist Health Services

Analysis of Anxiety, Stress, and Depression Trends in Pharmacy Students Pre- vs Post- Pandemic COVID-19 Education/Training/Stigma Anxiety Perceived Stress Depression

Analysis of Experiential Education Absence Policies for Mental Health Criteria Education/Training/Stigma Experiential Education Absence Policy Mental Health

Anticholinergics are Not Appropriate Treatments for Tardive Dyskinesia: Insights from an Expert Panel of Psychiatry and Neurology Healthcare Professionals Antipsychotics Tardive Dyskenesia Anticholinergic Movement Disorders

Antipsychotic-Induced Muscle-Specific Tyrosine Kinase (MuSK) Antibody Positive Myasthenia Gravis Antipsychotics Neurology Myasthenia Gravis

Antipsychotic-induced Tics in Autism Spectrum Disorder Antipsychotics Autism Spectrum Disorder Tics

Are REM Biomarkers Appropriate for Assessing Clinical Improvement in Major Depressive Disorder? Antidepressants Major Depression Therapeutic Drug Monitoring Sleep Disturbances Rapid Eye Movement

Assessing Acute Agitation Management at a Federal Health Care Center Acute Agitation Antipsychotics Anxiolytics VA

Assessing Documentation of Clozapine Trials in Patients Prescribed Antipsychotic Polypharmacy Regimens at Discharge Antipsychotics Schizophrenia Polypharmacy

Assessing the Applicability of Drug-Related Concentration (DRC) Factors for Antipsychotics in Forensic Psychiatric Patients Antipsychotics Monitoring Therapeutic Drug Monitoring Forensic Psychiatry

Assessing the Impact of an Innovate Behavioral Health Urgent Care Clinic Antipsychotics Health Equity Long-Acting Injectable Transitions Of Care

Assessment of Clozapine Therapeutic Drug Monitoring Therapeutic Drug Monitoring Clozapine

Assessment of Long-Acting Injectable Antipsychotic Use and Hospital Readmissions After a Pilot Formulary Expansion Antipsychotics Long-Acting Injectable

Assessment of Psychiatric Patients’ Actual QTc Intervals vs. Predicted QTc Prolongation Risk Drug-Drug Interactions Monitoring QTc Prolongation Torsades De Pointes

ATLAS - Addiction Treatment: Linking Access & Services Mobile Clinic Reducing Stigma-related Barriers in Rural NC Education/Training/Stigma Harm Reduction Health Equity Monitoring Opioid Use Disorder Substance Use Disorders Low Barrier Access Fentanyl

Baseline demographics and clinical characteristics from OASIS: Observational Study of Long-Acting Injectables in Schizophrenia Antipsychotics Long-Acting Injectable Schizophrenia

Behavioral Health Agitation Protocol Impact on As Needed Medication Use Acute Agitation Education/Training/Stigma Harm Reduction

Buprenorphine Micro-induction and Bridge Dosing Outcomes Opioid Use Disorder Substance Use Disorders Buprenorphine

Burnout Assessment of Pharmacy and Physician Assistant Program Students at a Historically Black College and University (HBCU) Health Equity Burnout

Burnout Assessment of Pharmacy Faculty at a Historically Black College and University (HBCU) Education/Training/Stigma Pharmacy Faculty Burnout

Changes in Attitudes and Behaviors Associated with Buprenorphine Best Practices Dissemination Education/Training/Stigma Harm Reduction Health Equity Opioid Use Disorder Substance Use Disorders

Characterization of Flumazenil Utilization in Electroconvulsive Therapy Anxiolytics Electroconvulsive Therapy

Cheers to Well-Being: Exploring the Impact of a Peer Support Program on Pharmacy Student Resilience and Happiness Education/Training/Stigma Well-Being Peer Support Resilience

Clinical Pharmacist Efforts to Increase Access to Buprenorphine in Veteran Population Adherence Education/Training/Stigma Opioid Use Disorder Substance Use Disorders VA Suboxone DEA

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants Antidepressants Pharmacogenomics

Clozapine, Caffeine, and Smoking: a Correlational Study and Initiation of Pharmacist‐Led Interventions to Improve Clinical Outcomes Antipsychotics Drug-Drug Interactions Schizophrenia Therapeutic Drug Monitoring VA

Clozapine-Induced Neutropenia in the Management of Treatment-Resistant Schizophrenia: A Case Report Antipsychotics Monitoring Schizophrenia Clozapine Neutropenia

Comparing Buprenorphine Prescription Patterns for Opioid Use Disorder (OUD) Before and After the Drug Addiction Treatment Act (DATA)-waiver Removal at a Hospital Healthcare System Opioid Use Disorder Substance Use Disorders

Comparing Effectiveness Between Different Antidepressants in Preventing Psychiatric Rehospitalization Adherence Antidepressants Major Depression Monitoring

Comparing the Cognitive Effect of Vortioxetine versus Other Selective Serotonin Receptor Inhibitors Antidepressants Geriatrics Major Depression Neurology VA

Comparison of High-Dose Olanzapine and Standard-Dose Olanzapine in Adult Patients at a County Psychiatric Hospital: A Retrospective Study Antipsychotics Bipolar Disorder Schizophrenia

Comparison of Kloxxado® and Narcan® Usage Following Updates to Computerized Patient Record System Opioid Use Disorder Substance Use Disorders Naloxone Narcan Kloxxado

Comparison of Pharmacist-Led Outpatient Depression Management to Current Prescriber-Led Depression Management Antidepressants Major Depression

Comparison of Rehospitalization Outcomes in the Veteran Population Administered Long-acting Injectable Naltrexone Versus Oral Naltrexone for Alcohol Use Disorder Before Discharge Alcohol Use Disorder Long-Acting Injectable Substance Use Disorders VA

Comparison of Treatment Outcomes in the Veteran Population Administered Aripiprazole Long-acting Injectable Versus Paliperidone Palmitate Long-acting Injectable for Bipolar Disorder in the Inpatient Setting Antipsychotics Bipolar Disorder Long-Acting Injectable VA

Correlation Between Higher Screen Time and Decreased Quality of Life in General Adolescents; An Analysis of YRBS Data from CDC Alcohol Use Disorder Antidepressants Child And Adolescent Psychiatry COVID-19 Major Depression Substance Use Disorders Screen Time Gaming Mental Health

Database Analysis for the Concomitant Use of an Immediate-Release Stimulant with an Extended-Release Stimulant for the Treatment of ADHD Adherence Child And Adolescent Psychiatry ADHD Real World Evidence

Development and Validation of an Instrument to Assess Patient Experience of Pharmacist-led Patient Medication Education Groups Education/Training/Stigma Medication Group Survey Multisite

Do Discharge Medications Prevent Rehospitalization Following Short-Term Crisis Stabilization at a County Psychiatric Hospital? Adherence Substance Use Disorders Rehospitalization Discharge Medications

Does Patient Attitude Toward Psychiatric Drug Therapy Impact Adherence to Their Medications? Adherence Antipsychotics Education/Training/Stigma Schizophrenia Perception Forensic Incompetent To Proceed

Duloxetine for Treatment Resistant Depression in Older Adults Antidepressants Geriatrics Major Depression VA

Effect of Clozapine for Depressive Symptoms in Black Patients with Schizophrenia or Schizoaffective Disorders Antipsychotics Schizophrenia Depression Clozapine Schizoaffective Disorder

Effectiveness of Tetrabenazine for the Treatment of Antipsychotic-induced Tardive Dyskinesia Antipsychotics VA Tetrabenazine Tardive Dyskinesia

Efficacy of KarXT (Xanomeline and Trospium) in Schizophrenia: Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials Antipsychotics Schizophrenia Muscarinic Receptor Agonist Xanomeline KarXT

Efficacy of Lumateperone in Pooled Short-Term Late-Phase Clinical Trials for Treatment of Major Depressive Episodes Associated With Bipolar II Disorder Lumateperone Major Depressive Episode Bipolar II Disorder

Efficacy, Tolerability, and Safety of AXS-05, a Novel Oral Antidepressant: Data From 3 Clinical Trials Antidepressants Major Depression Glutamatergic Therapy

Eliminating Drug Cost as Barrier to Medication Access Long-Acting Injectable Transitions Of Care Cost Savings

Emergency Room (ER) Visits Among Opioid Use Disorder (OUD) Patients Harm Reduction Long-Acting Injectable Opioid Use Disorder Emergency Room Overdose

Enhancing Buprenorphine Access and Identifying Treatment Barriers in Veterans with Opioid Use Disorder Opioid Use Disorder VA

Establishing a Database to Examine the Real-World Impact of Psychiatric Pharmacogenomic Testing in a Large Health System Antidepressants Antipsychotics Anxiolytics Bipolar Disorder Child And Adolescent Psychiatry Drug-Drug Interactions Major Depression Pharmacogenomics Post-Traumatic Stress Disorder/ PTSD Schizophrenia Mood Stabilizers Informatics Electronic Health Record Real-World Data

Establishing a Pharmacist-Run, Outpatient Long-Acting Injectable Antipsychotic Clinic in a Safety Net Hospital Adherence Antipsychotics Long-Acting Injectable

Establishing Monitoring Standards for Medication Therapy for Adults with Attention Deficit Hyperactivity Disorder (ADHD) VA ADHD Quality Improvement

Establishment of Behavioral Health Pharmacy Service Line at a Rural, Critical Access Indian Health Service Hospital System Health Equity Indian Health Service Rural Health Access To Care

Evaluating Outcomes of Psychotropic Drug Safety Initiative (PDSI) Management System for Management of Stimulant Use at a Medical Center Harm Reduction Monitoring Stimulants

Evaluating the Impact of an Automated Phone Outreach Program on Naloxone Prescribing to Veterans At-Risk for Opioid Overdose Harm Reduction Opioid Use Disorder Substance Use Disorders VA Naloxone

Evaluating the Impact of Photovoice on Self-Stigma Levels Among Individuals with Substance Use Concerns Alcohol Use Disorder Opioid Use Disorder Substance Use Disorders Self-Stigma Photovoice

Evaluating the Impact of Pre- and Post-Exams on Psychiatry Pharmacy Student Rotations: A Comprehensive Analysis Education/Training/Stigma Pegagogy Pharmacy Clinical Education Self-Assessment

Evaluating the Occurrence of Mania-Related Hospitalizations in Patients with Bipolar Disorder or Schizoaffective Disorder Receiving Antidepressant Therapy Antidepressants Bipolar Disorder VA Mania Schizoaffective Disorder

Evaluating the Use of a Pharmacist Led Initiative in Reducing Anticholinergic Burden at a State Psychiatric Hospital Acute Agitation Antidepressants Antipsychotics Anxiolytics Drug-Drug Interactions Education/Training/Stigma Monitoring Anticholinergic Burden Anticholinergic

Evaluation of Aripiprazole in the Treatment of Food Avoidant Behaviors among Adolescents with Anorexia Nervosa Antipsychotics Child And Adolescent Psychiatry Eating Disorders

Evaluation of Behavioral Health Pharmacy Advocates (BHPA), a Training Program for Pharmacy Personnel Education/Training/Stigma Behavioral Health Social Determinants Of Health Community Pharmacy

Evaluation of Bupropion Renal Dose Adjustment at an Inpatient Mental Health Facility to Optimize Patient Outcomes Antidepressants Anxiolytics Monitoring Mood Stabilizers

Evaluation of Current Valproic Acid Monitoring Practices in Inpatient Psychiatric Settings Bipolar Disorder Monitoring Therapeutic Drug Monitoring Mood Stabilizers

Evaluation of EKG Monitoring for Citalopram and Escitalopram Antidepressants Education/Training/Stigma Monitoring VA

Evaluation of Intentional Overdose Trends among Youth in Pennsylvania Before and During the COVID-19 Pandemic Child And Adolescent Psychiatry COVID-19 Suicide

Evaluation of Lithium Utilization at an Inpatient Mental Health Facility to Optimize Patient Outcomes Major Depression Mood Stabilizers

Evaluation of Medication Assisted Treatment (MAT) Program Enrollment and Treatment Retention, pre and post Drug Addiction Treatment Act (DATA) Waiver Elimination Adherence Education/Training/Stigma Monitoring Opioid Use Disorder Substance Use Disorders MAT DATA Waiver

Evaluation of Pharmacy Resident Burnout and Career Satisfaction Based on Residency Staffing Model Education/Training/Stigma Health Equity Burnout Residency Provider Wellbeing

Evaluation of the Impact of Concomitant Valproic Acid and Lorazepam Administration on Sedation Anxiolytics Drug-Drug Interactions Geriatrics Harm Reduction Mood Stabilizers

Evaluation of Treatment for Mania in Veterans with Bipolar I Disorder Antipsychotics Bipolar Disorder VA Mood Stabilizers

Evaluation of Workload and Burnout Among Psychiatric Pharmacists in the United States Education/Training/Stigma Transitions Of Care Burnout Workload

Examining The Correlation Between Follow-Up After Opioid Overdose And Clinical Outcomes At Los Angeles General Medical Center Education/Training/Stigma Harm Reduction Opioid Use Disorder Substance Use Disorders

Examining the Interventions of an Interdisciplinary Overdose Review Team (ORT) at a Rural Veterans Affairs Medical Center Harm Reduction Substance Use Disorders

Expanding Buprenorphine Access in a Primary Care Setting at an Ambulatory Outpatient Clinic Education/Training/Stigma Harm Reduction Opioid Use Disorder VA

Exploring the Harm Reduction Paradigm: The Role of Board-Certified Psychiatric Pharmacists Harm Reduction Substance Use Disorders Psychiatric Pharmacists Board-Certified Psychiatric Pharmacists

Exploring the Impact of Oral Antidepressant Class Selection on Esketamine-Treated Patients with Treatment-Resistant Depression Antidepressants Major Depression Monitoring Neurology Suicide Esketamine MADRS Treatment-Resistant Depression/ Treatment Refractory Depression NMDA Receptors

Exploring the Need for Weight Loss Interventions in Clozapine Patients at a Veterans Affairs Healthcare System Antipsychotics Schizophrenia VA Weight Management

Exploring the Potential Efficacy of Medical Cannabis for Major Depressive Disorder: A Systematic Review Major Depression Cannabis

Extent, patterns and predictors of contraception use among women of child-bearing age prescribed valproic acid in the United States Contraception Valproic Acid

Formation of a Working Alliance and Efficacy of a Digital Therapeutic to Treat Experiential Negative Symptoms of Schizophrenia Schizophrenia Prescription Digital Therapeutics Digital Working Alliance CT-155 Experiential Negative Symptoms

From Mute to Multilingual: Successful Treatment of Benzodiazepine-Refractory Chronic Catatonia with Memantine Monitoring Schizophrenia Catatonia

Glucagon-Like Peptide-1 Receptor Agonists and Risk for Depression Relapse Antidepressants Major Depression Suicide VA Antidiabetics

Healthcare Resource Utilization Following 6 Months of Treatment With Olanzapine/Samidorphan: Real-World Assessment of Patients With Schizophrenia or Bipolar I Disorder Antipsychotics Long-Acting Injectable Schizophrenia

High-Dose Vilazodone for the Treatment of Major Depressive Disorder: A Case Report Antidepressants Major Depression VA High-Dose

Hit Me with Your Best Shot: Implementation and Evaluation of Clinical Pharmacist Impact within a Long-Acting Injectable Antipsychotic Clinic at a Veterans Affairs Medical Center Antipsychotics Long-Acting Injectable Monitoring VA Quality Improvement

Impact of Antipsychotic Therapeutic Drug Monitoring (TDM) In a Mental Health Intensive Case Management Team Adherence Antipsychotics Long-Acting Injectable Monitoring Schizophrenia Therapeutic Drug Monitoring VA

Impact of AXS-05, an Oral NMDA Receptor Antagonist and Sigma-1 Receptor Agonist, on Anhedonic Symptoms in Major Depressive Disorder Antidepressants Major Depression Anhedonia

Impact of Clinical Pharmacist Intervention on a Neuropsychiatry and Behavioral Neurology Consult Service at a Free-standing Psychiatric Hospital Neurology Innovative Services

Impact of Combinatorial Pharmacogenomic Testing on Hospitalization Rates in a Real-World Dataset of Patients with Major Depressive Disorder Antidepressants Major Depression Pharmacogenomics

Impact of Medication Reviews by Pharmacists in Veterans Flagged High Risk for Suicide Antidepressants Antipsychotics Anxiolytics Harm Reduction Major Depression Stimulants Suicide VA

Impact of MH PGY2 Pharmacy Resident Outreach to Veterans with Potentially Untreated Opioid Use Disorder Recently Discharged from the Emergency Department Alcohol Use Disorder Harm Reduction Opioid Use Disorder Substance Use Disorders Transitions Of Care

Impact of Paroxetine 2D6 Inhibition in a Patient Transitioned From Oral Risperidone to Paliperidone Palmitate: A Case Report Acute Agitation Drug-Drug Interactions Long-Acting Injectable Autism Spectrum Disorder CYP2D6

Impact of Pharmacist Administration of Long-Acting Injectable Antipsychotics in Community Pharmacies Adherence Antipsychotics Long-Acting Injectable

Impact of Pharmacist Intervention on Appropriate Prescribed Stimulant Monitoring Among Veterans Harm Reduction Monitoring Stimulants VA

Impact of Pharmacist Led Contingency Management in Patients with Substance Use Disorders Adherence Alcohol Use Disorder Long-Acting Injectable Opioid Use Disorder Substance Use Disorders VA

Impact of Pharmacist-driven Intervention to Improve Long-acting Injectable Paliperidone Palmitate Administration and Ordering Antipsychotics Education/Training/Stigma Long-Acting Injectable Schizophrenia VA

Impact of Pharmacist-led Ambulatory Alcohol Detoxification Alcohol Use Disorder Substance Use Disorders VA Alcohol Withdrawal Alcohol Detoxification Clinical Pharmacist Practitioner

Impact of Pharmacist-Led Intervention in Veteran Patients With Positive Alcohol Use Disorder Identification Test on Access to Care and Clinical Metrics Alcohol Use Disorder Education/Training/Stigma Monitoring Substance Use Disorders VA

Impact of the Stimulant Shortage on Prescribing Patterns in a Child and Adolescent Psychiatry Outpatient Clinic Child And Adolescent Psychiatry Stimulants Drug Shortage

Impact of Viloxazine Extended-Release Capsules on Self-Rated Executive Function in a Long-Term, Phase 3, Open-Label Extension Trial of Adult ADHD ADHD Executive Function Deficits Adult Psychiatry

Impacts of COVID-19 Events on Clozapine Therapeutics: A Case Report Antipsychotics COVID-19 Schizophrenia Therapeutic Drug Monitoring

Implementation and Impact of Psychotropic Stewardship at a Large Academic Medical Center Adherence Antidepressants Antipsychotics Anxiolytics Drug-Drug Interactions Harm Reduction Long-Acting Injectable Monitoring Therapeutic Drug Monitoring Transitions Of Care

Implementation of a Pharmacist Driven Long-Acting Injectable Antipsychotic Transitions of Care Service Adherence Antipsychotics Education/Training/Stigma Long-Acting Injectable Schizophrenia Transitions Of Care

Implementation of A Pharmacist-Driven Long-Acting Injectable Antipsychotic Stewardship Program at VA Sierra Nevada Health Care System Antipsychotics Bipolar Disorder Long-Acting Injectable Schizophrenia VA

Implementation of a Pharmacist-led Mental Health Transitions of Care Clinic for Patients Discharged from a Residential Rehabilitation Treatment Program Adherence Transitions Of Care VA

Implementation of a Standardized Buprenorphine/Naloxone Induction Protocol on an Inpatient Psychiatry Unit Opioid Use Disorder Substance Use Disorders VA

Implementation of mMINDS Monitoring for Alcohol Withdrawal at an Academic Psychiatric Facility Alcohol Use Disorder Monitoring Alcohol Withdrawal

Improving the Utilization of Long-Acting Injectable Antipsychotics in Eligible Veterans at a Veterans Affairs Outpatient Health Care System Adherence Antipsychotics Bipolar Disorder Long-Acting Injectable Schizophrenia VA

Improving Veteran No-Show Rates at an Outpatient Mental Health Clinic Through Implementation of Measurement-Based Care Reminders VA Measurement Based Care No-Show Rate

Increase Access to Naloxone for Veterans Enrolled in Home Based Primary Care Opioid Use Disorder Stimulants Substance Use Disorders Naloxone Narcan

Influence of Patient Gender on Antipsychotic Selection in an Acute Inpatient Setting Antipsychotics Bipolar Disorder Health Equity Schizophrenia

Integration of a Clinical Pharmacist into Geriatric Psychiatry Treatment Team within a Veterans Affairs Healthcare System Geriatrics VA

Integration of a Psychiatric Clinical Pharmacist Practitioner into a Virtual Long-Term Opioid Therapy Reassessment Clinic Opioid Use Disorder VA Chronic Pain

Investigating Presence of Race Based Prescribing Differences in Hospitalized Patients Starting Buprenorphine using Transdermal Patch Micro-induction Method Health Equity Opioid Use Disorder

Investigating the Inhibitory Effects of Cannabis Smoke Condensate on Cytochrome P450 in the Human Lung Drug-Drug Interactions Neurology Lung Therapeutics Natural Product Cannabinoids

Investigation of the Effects of Medication Adherence on Hospital Admission Adherence Neurology Hospitalization Ambulatory Care

Involvement in Pediatric Psychiatry Pharmacy Intern Shift Improves Self-Efficacy/Comfort Child And Adolescent Psychiatry Education/Training/Stigma

Kratom: A Veteran’s Ally or Adversary? Opioid Use Disorder Substance Use Disorders VA Kratom

Lithium and Antipsychotics in Post-Partum Psychosis: Utilization of Pro re Nata Medications on an Inpatient Psychiatric Perinatal Unit Antipsychotics Postpartum Psychosis

Long Acting Injectable Antipsychotic Use and Discontinuation Rates in Pediatric Patients Using Medicaid Claims Data Antipsychotics Long-Acting Injectable Schizophrenia Medicaid Claims Discontinuation Rates Pediatric Psychiatric Treatment Adolescents Children

Long-Acting Injectable Antipsychotic Use in Pediatric and Adolescent Patients with Psychiatric Disorders Bipolar Disorder Child And Adolescent Psychiatry Long-Acting Injectable Schizophrenia

Long-term Follow-up of Implementation of Psychotropic Medication Utilization Parameters for Children and Adolescents in Texas Foster Care Child And Adolescent Psychiatry Monitoring Foster Children Psychotropic Utilization

Long-Term Metabolic Outcomes associated with KarXT (Xanomeline and Trospium): Interim Results from Pooled, Long-Term Safety Studies EMERGENT-4 and EMERGENT-5 Antipsychotics Schizophrenia Muscarinic Receptor Agonist Xanomeline KarXT Metabolic AEs

Lumateperone Treatment for Major Depressive Episodes with Mixed Features in Major Depressive Disorder and Bipolar I or Bipolar II Disorder Major Depression Lumateperone Bipolar Disorder Mixed Features

Managing Prescription Assistance Program Discontinuation at a Certified Community Behavioral Health Clinic Adherence Antipsychotics Monitoring Certified Community Behavioral Health Clinic Prescription Assistance Program

Medication Use Evaluation of Micro-Induction of Buprenorphine-Naloxone in a Stepped Care Model Opioid Use Disorder VA

Mental and Behavioral Health Supports and Services Provided by Pharmacists in Washington State Pharmacy Practice Health Services

Mental Healthcare Utilization Among Transgender Individuals in a Community Psychiatric Hospital Transgender Health Service Utilization

Naloxone Education Program Initiative in FMC, Devens Education/Training/Stigma Harm Reduction Health Equity Opioid Use Disorder Transitions Of Care

Opioid Treatment Programs, Healthcare Resource Utilization, and Healthcare Costs among patients initiating treatment with Buprenorphine Extended-Release Long-Acting Injectable Opioid Use Disorder Substance Use Disorders Residential Treatment Program Office-Based Opioid Treatment Intensive Outpatient Program Opioid Treatment Program

Overdose Prevention Strategies in High-Risk Youth Populations; Impact of Pharmacist-Driven Intervention and Interprofessional Collaboration Child And Adolescent Psychiatry Education/Training/Stigma Harm Reduction Suicide

Patients Requiring Early Administration of Maintenance Long-Acting Injectable Antipsychotic Dose Adherence Antipsychotics Bipolar Disorder Drug-Drug Interactions Long-Acting Injectable Monitoring Schizophrenia Administration Compliance Breakthrough

Pharmacist Managed Anxiety and Depression Treatment at a Federally Qualified Health Center Antidepressants Anxiolytics Major Depression Continuity Of Care Collaborative Practice Agreement

Pharmacist Run Pharmacotherapy Clinic Utilizing Behavioral Health Intervention Billing Schizophrenia Billing

Pharmacist-Led Intervention To Improve Adherence of Antidepressants and Address Potential Barriers Using Population Health Dashboard at a Rural Veterans Hospital Adherence Antidepressants Major Depression VA Pharmacist-Led Intervention

Pharmacist-Provided Education on Antipsychotic Monitoring Parameters after the COVID-19 Pandemic Antipsychotics COVID-19 Monitoring Schizophrenia Primary Care Adverse Drug Reaction Movement Disorders Metabolic Disorders

Pharmacists’ Attitudes Towards Psychedelics and their use in Therapy Antidepressants Anxiolytics Education/Training/Stigma Major Depression Post-Traumatic Stress Disorder/ PTSD Psychedelics

Pharmacokinetics of Viloxazine ER (Viloxazine Extended-Release Capsules) in Breastmilk of Healthy Lactating Women ADHD Women's Health Lactation Nonstimulants

Pharmacy Students Advancing Mental Health Equity in an Underserved Racial/Ethnic Community Education/Training/Stigma Harm Reduction Health Equity

Prescribing Patterns of Valproic Acid and Derivatives in Nursing Home Residents with Dementia Acute Agitation Geriatrics Harm Reduction Monitoring Therapeutic Drug Monitoring VA Mood Stabilizers Dementia Quality Improvement

Prevalence of Asymptomatic Bacteriuria in Psychiatric Patients at a County Safety Net Hospital Medical Comorbidity Antimicrobial Stewardship

Protocol Deviations of Inpatient Medication Order Adjustments Associated with Electroconvulsive Therapy Bipolar Disorder Major Depression Schizophrenia Electroconvulsive Therapy Quality Improvement

Providing Targeted Outreach for Pharmacogenomic Testing to Actionable Veterans with Post Traumatic Stress Disorder (PTSD) Antidepressants Pharmacogenomics Post-Traumatic Stress Disorder/ PTSD Therapeutic Drug Monitoring VA

Psychotropic Prescribing Patterns Among Forensic Psychiatric Inpatients with and without Borderline Personality Disorder Suicide Borderline Personality Disorder

Psychotropic Stewardship: Review of Antipsychotic Polypharmacy at Discharge from a Free-standing Psychiatric Hospital Antipsychotics Transitions Of Care

Quality Improvement for Pediatric Opioid, Benzodiazepine, and Alcohol Detoxification Treatment through Development and Implementation of a Standardized System Wide Protocol Alcohol Use Disorder Anxiolytics Child And Adolescent Psychiatry Opioid Use Disorder Substance Use Disorders Substance Detoxification Standard Protocol

Re-Evaluation of Stimulant Prescribing Patterns of Veterans Affairs Outpatient Mental Health Providers: A Five-Year Follow Up Study Monitoring Stimulants

Real-World Clinical Experience of Dexmedetomidine Sublingual Film for Agitation in Adults with Schizophrenia or Bipolar Disorder Acute Agitation Bipolar Disorder Schizophrenia

Relapse Rates Among Veterans on Maintenance Doses of Oral Buprenorphine/Naloxone versus Subcutaneous Extended-Release Buprenorphine for Opioid Use Disorder Long-Acting Injectable Opioid Use Disorder Substance Use Disorders VA

Relevance of Psychiatry-Focused Pharmacogenomic Test Results to Non-Psychiatric Medications Treatment In Pediatric and Adult Patients Antidepressants Antipsychotics Anxiolytics Bipolar Disorder Child And Adolescent Psychiatry Major Depression Pharmacogenomics Post-Traumatic Stress Disorder/ PTSD Schizophrenia Mood Stabilizers Informatics Electronic Health Record Real-World Data

Retrospective Review of Patients’ Receiving Long-Acting Injectables on Inpatient Behavioral Units to Assess the Impact of Pharmacist Led Administration in Outpatient and Retail Settings Antipsychotics Long-Acting Injectable Transitions Of Care

Role of Board-Certified Psychiatric Pharmacists in Child and Adolescent Psychiatry Child And Adolescent Psychiatry Psychotropic Stewardship

Safety and Tolerability of KarXT (Xanomeline and Trospium): Pooled Results From the Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials Antipsychotics Schizophrenia Muscarinic Receptor Agonist Xanomeline KarXT

Standardizing the Inpatient Medication Reconciliation Process for Long-Acting Injectable Antipsychotics Antipsychotics Long-Acting Injectable Transitions Of Care

Student Perceptions of Relaxation Before And After Exposure to Relaxation Tools And Techniques Education/Training/Stigma Mental Health

Switching Patients With Schizophrenia to TV-46000, a Long-Acting Subcutaneous Antipsychotic (LASCA), From Risperidone Microspheres (R064766): An Exploration of Population Pharmacokinetic (PopPK)–Based Strategies Antipsychotics Long-Acting Injectable Schizophrenia Risperidone Switching Intramuscular Subcutaneous TV-46000

The Effect of Mental Health Clinical Pharmacy Specialist Intervention on Cardiovascular Safety and Urine Drug Screen Monitoring for Patients Prescribed Stimulants at the Cincinnati Veterans Affairs Medical Center Monitoring Stimulants VA

The Effect of Montelukast on Suicidal Ideation in the Veteran Population Antidepressants Suicide Therapeutic Drug Monitoring VA

The Impact of Long-Acting Injectable Antipsychotic Therapies Versus Oral Antipsychotic Therapies on Adherence and Clinical Outcomes Adherence Antipsychotics Long-Acting Injectable Schizophrenia

The Importance of Incorporating Drug-Drug Interactions and Lifestyle Factors in Pharmacogenomics-Guided Medication Management for Patients with Major Depressive Disorder in a Randomized Controlled Trial   Antidepressants Drug-Drug Interactions Major Depression Pharmacogenomics

The Role of Social Media on Dissemination of Information Regarding Antidepressants Adherence Antidepressants Education/Training/Stigma Social Media

The Safety And Efficacy of Antidepressants As An Alternative Therapy In The Treatment Of ADHD In Pediatric Populations: A Review Of The Literature Antidepressants Child And Adolescent Psychiatry Stimulants

Transition of Veterans with Mental Health Disorders from Mental Health Clinic to Primary Care Clinic Antidepressants Anxiolytics Transitions Of Care VA

Treatment and Economic Challenges when Treating Patients with Agitation Associated with Schizophrenia or Bipolar Disorder in the Emergency Department (ED) Acute Agitation Bipolar Disorder Schizophrenia

Treatment Engagement of Patients Initiated on Extended-Release Injectable Naltrexone for Alcohol Use Disorder in the Inpatient Setting Alcohol Use Disorder Long-Acting Injectable Transitions Of Care

Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen Antipsychotics Long-Acting Injectable Schizophrenia Persistence Healthcare Resource Use

Treatment patterns and outcomes from OASIS: Observational Study of Long-Acting Injectables in Schizophrenia Antipsychotics Long-Acting Injectable Schizophrenia

Treatment Resistant Priapism in a 61-Year-Old Male After Combined Use of Trazodone, Quetiapine, and Fluoxetine. Antidepressants Antipsychotics

Trends in the Use of Co - Prescribed Benzodiazepines and Opioids in the United States: 2011 - 2020 Adherence Alcohol Use Disorder Anxiolytics Drug-Drug Interactions Monitoring Opioid Use Disorder Sleep Disorder Substance Use Disorders Drug Drug Interaction Black Box Warning Prescribing Guidelines Pain Management Depression

Unveiling Stigma in Healthcare: An Exploration of Student Pharmacists’, Nurses’ and Physicians’ Attitudes Towards Mental Illness Alcohol Use Disorder Bipolar Disorder Education/Training/Stigma Harm Reduction Major Depression Opioid Use Disorder Post-Traumatic Stress Disorder/ PTSD Schizophrenia Sleep Disorder Substance Use Disorders Suicide

Utility of a Clinical Pharmacist Practitioner in the Deprescribing of Z-hypnotics in Older Adults Geriatrics Sleep Disorder VA

Utilization of Lidocaine/Epinephrine to Minimize Injection Site Pain for Patients Receiving Subcutaneous Extended-Release Buprenorphine Education/Training/Stigma Harm Reduction Long-Acting Injectable Opioid Use Disorder Substance Use Disorders

Utilizing Therapeutic Drug Monitoring to Optimize Dosing of Antipsychotics on Inpatient Behavioral Health Units Antipsychotics Monitoring Therapeutic Drug Monitoring

Viloxazine ER Administered with Psychostimulants in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Phase IV Safety Trial Child And Adolescent Psychiatry Stimulants ADHD Nonstimulants

Zuranolone and Brexanolone: A Review of Novel Treatment Options for Moderate to Severe Postpartum Depression Major Depression Postpartum Depression